Your session is about to expire
← Back to Search
Virus Therapy
HPV Self-Collection for Cervical Cancer Prevention
N/A
Recruiting
Led By Vikrant V Sahasrabuddhe
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Is 25 years or older
Has an intact cervix
Must not have
Has had a complete or partial hysterectomy, either supracervical or involving removal of the cervix, via self-report or confirmation via medical records
Is experiencing unusual bleeding or pelvic pain
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one-time, up to 90 days
Awards & highlights
Summary
This trial aims to test if self-collected vaginal samples can be used for HPV testing to improve cervical cancer prevention. HPV is a virus that can cause cervical cancer, but many people are not diagnosed early
Who is the study for?
This trial is for individuals referred for colposcopy or cervical excisional procedures to prevent cervical cancer. Participants will use self-collection kits for HPV testing, which could offer more comfort and flexibility than traditional clinic-based tests.
What is being tested?
The SHIP Trial evaluates the clinical accuracy of HPV testing using self-collected vaginal samples versus clinician-collected cervical samples. It aims to inform FDA regulatory reviews of these self-collection methods for cervical cancer screening.
What are the potential side effects?
There are generally no direct side effects from participating in this study as it involves non-invasive collection of samples. However, some individuals might experience discomfort or emotional distress during self-sampling.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 25 years old or older.
Select...
My cervix has not been removed.
Select...
I was referred for a colposcopy or cervical procedure after an abnormal cervical cancer screening in the last year.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a hysterectomy, either partial or complete.
Select...
I am experiencing unusual bleeding or pelvic pain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one-time, up to 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one-time, up to 90 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinical sensitivity for clinician-collected (CC) samples
Clinical sensitivity for self-collected (SC) samples
Clinical specificity for CC samples
+11 moreOther study objectives
Human factors affecting acceptability
Human factors affecting references for self-collection
Human factors affecting usability
Trial Design
1Treatment groups
Experimental Treatment
Group I: Prevention (self-collected and clinician-collected samples)Experimental Treatment9 Interventions
Patients undergo self-collection of a vaginal sample and then undergo clinician-collection of a cervical test sample. Patients then undergo SOC colposcopy with cervical biopsy/endocervical curettage and/or cervical excisional procedures as clinically indicated.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020
HPV Self-Collection
2022
N/A
~20
Excision
2017
N/A
~200
Colposcopy
2009
Completed Phase 3
~64500
Cervical Biopsy
2012
Completed Phase 1
~10
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)Lead Sponsor
13,872 Previous Clinical Trials
41,010,246 Total Patients Enrolled
Vikrant V SahasrabuddhePrincipal InvestigatorNational Cancer Institute Division of Cancer Prevention
2 Previous Clinical Trials
1,020 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger